Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation

Chiara Rovera, Massimo Carlo Mauri, Elena Bertin, Chiara Di Pace, Silvia Paletta, Alessandra Reggiori, Ilaria Francesca De Gaspari, Dario Cattaneo, Daniela Mari, Alfredo Carlo Altamura

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: The aim of this open-label naturalistic study was to assess clinical outcomes and the predictive value of duloxetine plasma levels in major depressive disorder in the elderly. Methods: This naturalistic, open-label design involved 35 outpatients aged between 65 and 87 years. Duloxetine plasma levels were collected in 24 patients after the first month. Patients were evaluated using 21-item Hamilton Rating Scales for Depression, Hamilton Rating Scales for Anxiety, the Clinical Global Impression Severity, Mini Mental State Examination, Cumulative Illness Rating Scale, Barthel Index and Beck's Depression Inventory. Results: Duloxetine plasma levels at T2 ranged from 4.9 to 201.9 ng/mL without a significant correlation between duloxetine dose and plasma levels. A significant improvement in mean 21-item Hamilton Rating Scales for Depression total scores at T2,T3, T4, T9 and T12 and a progressive significantly decrease of the mean Hamilton Rating Scales for Anxiety scores from T3 to T12 were observed. Conclusions: The levels of duloxetine in plasma do not correlate with a greater clinical improvement, indeed appear to adversely affect the improvement of the Beck Depression Inventory and Hamilton Rating Scales for Anxiety. This could be explained by an increase in side effects that may aggravate the discomfort felt by the patient.

Original languageEnglish
Pages (from-to)349-355
Number of pages7
JournalHuman Psychopharmacology
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Depression
Pharmaceutical Preparations
Anxiety
Equipment and Supplies
Major Depressive Disorder
Outpatients
Duloxetine Hydrochloride

Keywords

  • duloxetine
  • elderly
  • major depressive disorder
  • plasma level

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Duloxetine in elderly major depression disorder : effectiveness and drug plasma level evaluation. / Rovera, Chiara; Mauri, Massimo Carlo; Bertin, Elena; Di Pace, Chiara; Paletta, Silvia; Reggiori, Alessandra; De Gaspari, Ilaria Francesca; Cattaneo, Dario; Mari, Daniela; Altamura, Alfredo Carlo.

In: Human Psychopharmacology, 01.09.2016, p. 349-355.

Research output: Contribution to journalArticle

Rovera, C, Mauri, MC, Bertin, E, Di Pace, C, Paletta, S, Reggiori, A, De Gaspari, IF, Cattaneo, D, Mari, D & Altamura, AC 2016, 'Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation', Human Psychopharmacology, pp. 349-355. https://doi.org/10.1002/hup.2544
Rovera, Chiara ; Mauri, Massimo Carlo ; Bertin, Elena ; Di Pace, Chiara ; Paletta, Silvia ; Reggiori, Alessandra ; De Gaspari, Ilaria Francesca ; Cattaneo, Dario ; Mari, Daniela ; Altamura, Alfredo Carlo. / Duloxetine in elderly major depression disorder : effectiveness and drug plasma level evaluation. In: Human Psychopharmacology. 2016 ; pp. 349-355.
@article{b899b8c615a44ce0844409b637d12583,
title = "Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation",
abstract = "Objective: The aim of this open-label naturalistic study was to assess clinical outcomes and the predictive value of duloxetine plasma levels in major depressive disorder in the elderly. Methods: This naturalistic, open-label design involved 35 outpatients aged between 65 and 87 years. Duloxetine plasma levels were collected in 24 patients after the first month. Patients were evaluated using 21-item Hamilton Rating Scales for Depression, Hamilton Rating Scales for Anxiety, the Clinical Global Impression Severity, Mini Mental State Examination, Cumulative Illness Rating Scale, Barthel Index and Beck's Depression Inventory. Results: Duloxetine plasma levels at T2 ranged from 4.9 to 201.9 ng/mL without a significant correlation between duloxetine dose and plasma levels. A significant improvement in mean 21-item Hamilton Rating Scales for Depression total scores at T2,T3, T4, T9 and T12 and a progressive significantly decrease of the mean Hamilton Rating Scales for Anxiety scores from T3 to T12 were observed. Conclusions: The levels of duloxetine in plasma do not correlate with a greater clinical improvement, indeed appear to adversely affect the improvement of the Beck Depression Inventory and Hamilton Rating Scales for Anxiety. This could be explained by an increase in side effects that may aggravate the discomfort felt by the patient.",
keywords = "duloxetine, elderly, major depressive disorder, plasma level",
author = "Chiara Rovera and Mauri, {Massimo Carlo} and Elena Bertin and {Di Pace}, Chiara and Silvia Paletta and Alessandra Reggiori and {De Gaspari}, {Ilaria Francesca} and Dario Cattaneo and Daniela Mari and Altamura, {Alfredo Carlo}",
year = "2016",
month = "9",
day = "1",
doi = "10.1002/hup.2544",
language = "English",
pages = "349--355",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Duloxetine in elderly major depression disorder

T2 - effectiveness and drug plasma level evaluation

AU - Rovera, Chiara

AU - Mauri, Massimo Carlo

AU - Bertin, Elena

AU - Di Pace, Chiara

AU - Paletta, Silvia

AU - Reggiori, Alessandra

AU - De Gaspari, Ilaria Francesca

AU - Cattaneo, Dario

AU - Mari, Daniela

AU - Altamura, Alfredo Carlo

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objective: The aim of this open-label naturalistic study was to assess clinical outcomes and the predictive value of duloxetine plasma levels in major depressive disorder in the elderly. Methods: This naturalistic, open-label design involved 35 outpatients aged between 65 and 87 years. Duloxetine plasma levels were collected in 24 patients after the first month. Patients were evaluated using 21-item Hamilton Rating Scales for Depression, Hamilton Rating Scales for Anxiety, the Clinical Global Impression Severity, Mini Mental State Examination, Cumulative Illness Rating Scale, Barthel Index and Beck's Depression Inventory. Results: Duloxetine plasma levels at T2 ranged from 4.9 to 201.9 ng/mL without a significant correlation between duloxetine dose and plasma levels. A significant improvement in mean 21-item Hamilton Rating Scales for Depression total scores at T2,T3, T4, T9 and T12 and a progressive significantly decrease of the mean Hamilton Rating Scales for Anxiety scores from T3 to T12 were observed. Conclusions: The levels of duloxetine in plasma do not correlate with a greater clinical improvement, indeed appear to adversely affect the improvement of the Beck Depression Inventory and Hamilton Rating Scales for Anxiety. This could be explained by an increase in side effects that may aggravate the discomfort felt by the patient.

AB - Objective: The aim of this open-label naturalistic study was to assess clinical outcomes and the predictive value of duloxetine plasma levels in major depressive disorder in the elderly. Methods: This naturalistic, open-label design involved 35 outpatients aged between 65 and 87 years. Duloxetine plasma levels were collected in 24 patients after the first month. Patients were evaluated using 21-item Hamilton Rating Scales for Depression, Hamilton Rating Scales for Anxiety, the Clinical Global Impression Severity, Mini Mental State Examination, Cumulative Illness Rating Scale, Barthel Index and Beck's Depression Inventory. Results: Duloxetine plasma levels at T2 ranged from 4.9 to 201.9 ng/mL without a significant correlation between duloxetine dose and plasma levels. A significant improvement in mean 21-item Hamilton Rating Scales for Depression total scores at T2,T3, T4, T9 and T12 and a progressive significantly decrease of the mean Hamilton Rating Scales for Anxiety scores from T3 to T12 were observed. Conclusions: The levels of duloxetine in plasma do not correlate with a greater clinical improvement, indeed appear to adversely affect the improvement of the Beck Depression Inventory and Hamilton Rating Scales for Anxiety. This could be explained by an increase in side effects that may aggravate the discomfort felt by the patient.

KW - duloxetine

KW - elderly

KW - major depressive disorder

KW - plasma level

UR - http://www.scopus.com/inward/record.url?scp=84988450778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988450778&partnerID=8YFLogxK

U2 - 10.1002/hup.2544

DO - 10.1002/hup.2544

M3 - Article

C2 - 27400882

AN - SCOPUS:84988450778

SP - 349

EP - 355

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

ER -